Ignite Creation Date:
2024-07-17 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500676
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-08
Brief Title:
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Sponsor:
Genfleet Therapeutics Shanghai Inc
Organization:
Genfleet Therapeutics Shanghai Inc
Study Overview
Official Title:
An Open-Label Phase III Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open-label phase III study to explore the safety tolerability pharmacokinetics PK and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None